We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.40 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.40 | 3.40 | 3.40 | 3.40 | 3.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 07/5/2024 10:24 by troutisout Good interview.Rather than wait until the new traction is proven, those investors looking for maximum reward, must be looking at the current price and thinking about adding... |
Posted at 18/1/2024 08:02 by cyberbub The CFO on the Investor Meets Company presentation did indeed say that cash was flat from September to October and that they had already paid out the redundancy payments from the downsizing. |
Posted at 10/1/2024 18:13 by cumnor Yea, question is does management really have the expertise and clout to sell the brand to big investors-not penny punters. Should be an easy sell in reality-even getting the NCI in the US to show a remote interest in their antibody library is some feat one typically underappreciated by gormless UK II analysts who don't know their ars..from their elbows, and confirms the science side of things is worthwhile.Persuading IIs that a single antibody with prospects (look at GSKs deal for early phase 2 respiratory AB they paid a billion + for the right to develop-ex China-which hasn't even been approved for clinical use yet to give one an idea of the scale and potential here. I'm afraid mgmt don't seem up to it, especially if they have to resort to Proactive to sell the story for funds. |
Posted at 26/12/2023 21:28 by gtc1508 hxxps://youtu.be/8y_Watch the investor presentation where CEO talks around this. The NCI partnership is cash neutral but fusion have agreed NCI can retain the antibodies they are targeting. Key thing is the company have agreed the limited set with the NCI, they can also work on these with clients and they are happy they have not lost anything. The key thing for the company is the validation by the world leading research agency of their world first prototype technology. Aka if they are succcessul then the technology is proven at zero cost to fusion and will be highly attractive in the market and likely that NCI will wish to continue to use on a fee for use basis(or buyout) on the other side |
Posted at 08/12/2023 10:06 by jaknife luckyabbeygale,Well done on making a quick profit on a scalp trade. You appear to be referring to this post: ==================== luckyabbeygale, "I missed the rise and was worried the sells start coming again. Therefore I only bought 200 pp at 6p and now I wish I bought a lot more." You'll get the chance to buy a lot more at a lot lower, the accounts note that they expect to place in Q1. JakNife ==================== This comment was based on the words in GDR's accounts: "The Group and Company does not currently have sufficient cash resources to continue as a going concern during the forecast period due to the time expected to be needed to gain commercial traction in its revenues. Therefore, the Company will need to raise further equity, or other funding, in early 2024 in order to continue as a going concern. The forecasts prepared by the Directors include a plan to raise additional funds from equity investors or debt providers in early 2024 to allow the Company to continue as a going concern." [my bold] see: Q1 is a period of time that starts on 1 Jan 2024 and ends on 31 March 2024. I will entertain complaints about my post above at the end of Q1. In the meantime I wish you a joyous Christmas! JakNife |
Posted at 07/12/2023 13:04 by bones698 Must admit unless they manage to sign some decent deals they will be raising cash in the next few months for sure . Even with a big contract which hasn't arrived and is never guaranteed until it's signed the cash position is precarious and the longer they leave it and closer they get to running out of cash the worse the raise will be for investors ..The mkt cap is minimal just over a million leaks anything decent could see this rocket but the odds of that are slim and it's this price for a reason. I'll wait for news and financing before even thinking of investing here it's just very very high risk |
Posted at 06/12/2023 17:18 by clocktower LOL daniel - his warnings were spot on when the nasty Paul Warwick was trying desperately to shore up his position by ramping this and saying he was getting his friends to buy even when it bounced to 95p, as I think he must have swallowed hook sink and line what the previous Board of Directors feed him.I never like to see Private Investors make losses but in his case I have no sympathy at all, due to his actions. I have not followed it closely since they did the raise at the huge discount after the first profitable bounce, while warning this share is a dog. Still if you to have taken the bait, I hope you will not get hurt if and when the hook bites. |
Posted at 04/10/2023 10:10 by bobaxe1 Investor meet company at 11am |
Posted at 01/8/2023 07:52 by soultrading The rvr down here is very much in new investors favour. This has the potential to be huge from these levels |
Posted at 19/5/2023 11:34 by timbo003 I see that the CFO has scarpered, not surprised really as he has been telling investors for the last couple of years that the company shouldn't require further funds to reach cash break even 😦 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
